钠-葡萄糖共转运蛋白2抑制剂在老年2型糖尿病合并常见心血管疾病中的应用进展
Advances in application of sodium-glucose co-transporter 2 inhibitor in elderly type 2 diabetes mellitus patients with concomitant common cardiovascular diseases
张辉 1李泱 2刘传斌1
作者信息
- 1. 中国人民解放军总医院京西医疗区,北京 100144
- 2. 中国人民解放军总医院第六医学中心心血管病学部,北京 100048
- 折叠
摘要
老年2型糖尿病(T2DM)患者常有多病共存现象,而合并心血管疾病(CVD)最为常见,是其致残、致死的首要原因.钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)是一种新型降糖药物,其心血管保护作用受到广泛关注,在老年T2DM与CVD共病的治疗上展现出良好的前景.本文就SGLT2i在T2DM合并心力衰竭、高血压、动脉粥样硬化、心肌梗死等常见CVD中的应用研究进展作一综述.
Abstract
Elderly patients with type 2 diabetes mellitus(T2DM)often have multiple coexisting diseases,and the complication of cardiovascular diseases(CVD)is the most common,which is the primary cause of disability and death.Sodium-glucose co-transporter protein 2 inhibitor(SGLT2i)is a novel hypoglycemic agent,which has received widespread attention for its cardio-protective effects,and shows good prospects for the treatment of co-morbidities of T2DM and CVD in the elderly.In this article,we reviewed the progress of SGLT2i in T2DM combined with heart failure,hypertension,atherosclerosis,myocardial infarction and other common CVD.
关键词
糖尿病,2型/钠-葡萄糖共转运蛋白2抑制剂/老年共病/心血管疾病/心力衰竭Key words
diabetes mellitus,type 2/sodium-glucose co-transporter protein 2 inhibitor/geriatric co-morbidities/cardiovascular diseases/heart failure引用本文复制引用
基金项目
国家自然科学基金(82200366)
国家自然科学基金(82370327)
出版年
2024
NETL
NSTL
万方数据